Minnesota Clinical Trials Report — June 2026

For Minnesotans considering participation in clinical research, June 2026 presents both urgent opportunities and exciting new avenues for contribution. A total of 131 clinical trials are slated to conclude enrollment within the next 90 days, meaning time is running out to join these studies. Among these are 21 trials actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various conditions, from cancers to metabolic disorders, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Ovarian cancer (3 trials)
• Ulcerative colitis (3 trials)
• Obesity (3 trials)
• Atrial fibrillation (3 trials)
• Prader-Willi syndrome (2 trials)
• Sepsis (2 trials)
• Advanced breast cancer (2 trials)
• Chronic pain (2 trials)
• Aortic regurgitation (2 trials)

Major Research Initiatives Launch Across Minnesota

This month, Minnesota welcomes 26 new clinical trials, a slight decrease from the 33 trials that opened in May 2026. Despite this, the new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraines, as well as crucial vaccine development.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring a substantial global Phase 3 trial, NCT07654361, titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This study aims to enroll 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo, in combination with a reduced-calorie diet.
• Another significant Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study seeks 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus (T2DM).
• For those experiencing migraines, Kallyope Inc. is leading two important Phase 3 studies. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized, multicenter trial targeting 1,800 participants to assess elismetrep's efficacy, safety, and tolerability compared to placebo. A companion study, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," plans for 1,000 participants to evaluate the long-term safety and tolerability of intermittent use of elismetrep.
• Pfizer is sponsoring NCT07660198, a Phase 3 "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents." This trial aims to enroll 1,200 participants to learn about the safety and immune response of a new pneumococcal vaccine against pneumonia, meningitis, and otitis media in children and adolescents.
• AstraZeneca is launching NCT07662135, a Phase 3 study to investigate "The Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This study seeks 900 participants to evaluate a new treatment for T2DM patients with impaired renal function.
• Beyond drug trials, Mayo Clinic is sponsoring NCT07670520, "Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial," which plans to enroll 2,260 participants to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors.
• For individuals and families affected by Down syndrome, RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term study will follow 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences over time.

New Research Opportunities Across Conditions and Interventions

The 26 new trials opening this month in Minnesota cover a diverse range of health conditions, with a strong focus on metabolic health. The most common conditions addressed by these new studies include:

• Overweight (2 trials)
• Obesity (2 trials)
• Chronic weight management (2 trials)
• Acute or chronic coronary artery disease (1 trial)
• Advanced cancer (1 trial)
• Advanced net of GI origin (1 trial)
• Adenocarcinoma of the prostate (1 trial)
• Advanced prostate cancer (1 trial)
• Back pain (1 trial)
• Cannabis use (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 10 of the new studies. Other intervention types include behavioral (4 trials), device (5 trials), and procedure (3 trials), reflecting a broad approach to medical advancement.

Geographic Reach: Twin Cities and Rochester Lead the Way

Minnesota's clinical research landscape continues to be robust, with 2,072 clinical trials currently recruiting across 71 cities and 723 research sites statewide. This month, the majority of new research initiatives are concentrated in major metropolitan areas, making access convenient for many residents. The cities with the most new trials include:

• Rochester (12 new trials)
• Minneapolis (10 new trials)
• Mankato (3 new trials)
• Saint Paul (1 new trial)
• Richfield (1 new trial)
• Duluth (1 new trial)
• Saint Louis Park (1 new trial)

This distribution highlights the significant research hubs in Rochester and Minneapolis, while also showing expanding opportunities in other parts of the state.

Opportunities for All: Healthy Volunteers and Diverse Participation

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. As mentioned, 21 trials closing soon are seeking healthy volunteers. Additionally, of the 26 new trials launched this month, 4 are actively seeking healthy participants. Statewide, a total of 243 clinical trials are currently recruiting healthy volunteers, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Minnesota are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 5 include children as participants, and 23 include older adults, ensuring that research benefits diverse age groups. There is also 1 female-only trial and 1 male-only trial. Academic institutions continue to play a vital role in the state's research ecosystem, with Mayo Clinic sponsoring 9 of the new trials and the University of Minnesota sponsoring 3. Industry sponsors are also driving significant research efforts, with 8 new trials sponsored by pharmaceutical companies such as Kallyope Inc., Gasherbrum Bio, Inc., and Pfizer.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Minnesota.